Evidence map›Paper›PMID 30899903›Full record

ReviewMayo Clinic proceedings. Innovations, quality & outcomes2019

Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure.

Courtney Premer, Anthony J Kanelidis, Joshua M Hare, Ivonne Hernandez Schulman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Courtney PremerInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL.
Anthony J KanelidisDepartment of Medicine, University of Chicago, Chicago, IL.
Joshua M HareInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL.
Ivonne Hernandez SchulmanInterdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL.
University of Miami · USUniversity of Chicago · US

Funding

Cardioprotective Effect of Growth Hormone Releasing HormoneR01HL107110 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2020
$5.9M
Cell Based Therapy for Non-Ischemic Dilated CardiomyopathyUM1HL113460 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2012 to 2018
$4.3M
Mesenchymal stem cell therapy for endothelial dysfunction in diabetesR01HL134558 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2016 to 2020
$3.2M
Nitric Oxide and sex differences in cardiac repairR01HL137355 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL107110NHLBI NIH HHS R01 HL134558NHLBI NIH HHS R01 HL137355NHLBI NIH HHS UM1 HL113460
6 · The paper itself

Abstract

Endothelial dysfunction is characterized by nitric oxide dysregulation and an altered redox state. Oxidative stress and inflammatory markers prevail, thus promoting atherogenesis and hypertension, important risk factors for the development and progression of heart failure. There has been a reemerging interest in the role that endothelial dysfunction plays in the failing circulation. Accordingly, patients with heart failure are being clinically assessed for endothelial dysfunction via various methods, including flow-mediated vasodilation, peripheral arterial tonometry, quantification of circulating endothelial progenitor cells, and early and late endothelial progenitor cell outgrowth measurements. Although the mechanisms underlying endothelial dysfunction are intimately related to cardiovascular disease and heart failure, it remains unclear whether targeting endothelial dysfunction is a feasible strategy for ameliorating heart failure progression. This review focuses on the pathophysiology of endothelial dysfunction, the mechanisms linking endothelial dysfunction and heart failure, and the various diagnostic methods currently used to measure endothelial function, ultimately highlighting the therapeutic implications of targeting endothelial dysfunction for the treatment of heart failure.

Indexed as

Ach, acetylcholineCAD, coronary artery diseasecGMP, cyclic guanosine monophosphateCVD, cardiovascular diseaseECFC, endothelial colony-forming cellEDHF, endothelium-derived hyperpolarizing factoreNOS, endothelial nitric oxide synthaseEPC-CFU, EPC–colony-forming unitEPC, endothelial progenitor cellFMD, flow-mediated vasodilationH2O2, hydrogen peroxideHF, heart failureHFpEF, HF with preserved ejection fractionHFrEF, HF with reduced ejection fractionIVUS, intravascular ultrasoundLVEF, left ventricular ejection fractionNO, nitric oxideNOS, NO synthasePAT, peripheral arterial tonometryQCA, quantitative coronary angiographyROS, reactive oxygen species

Identifiers

PMID30899903
PMCPMC6408687
OpenAlexW2916506247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.